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Abstract 
  
Aims: Botulinum toxin A (BTX-A) and sacral neuromodulation (SNS) are well established 
treatments for overactive bladder (OAB) and appear as standard of care in refractory cases in many 
international urological guidelines related to the subject. Despite long term use over decades their 
‘exact’ working mechanisms are not entirely clear. At the ICI-RS meeting in Bristol in 2016 a think 
tank was convened to address the question. Methods: The think tank conducted a literature review 
and an expert consensus meeting focussing on current established mechanisms and what could 
be learned from clinical experience and objective urodynamic data. Results: Clinical and 
urodynamic results with BTX-A suggests effects on both filling and voiding parts of the micturition 
cycle. The salient data in this regard is presented as well as additional studies related to the 
urothelium and evidence for more central effects. Urodynamics have shown consistently increases 
in cystometric, bladder compliance and reductions in detrusor pressures during filling, however 
post void residuals also increase in a dose dependent fashion. During SNM activation of somatic 
afferent nerves inhibits bladder sensory pathways and reflex bladder hyperactivity. Evidence in the 
cat model suggests the inhibition of bladder activity occurs primarily in the CNS by inhibition of the 
ascending or descending pathways of the spinobulbospinal micturition reflex. Urodynamics have 
suggested improvement in filling phase such as increases in cystometric capacity and reduction in 
detrusor pressures during filling with little observed effects on voiding parameters. Conclusions: 
The working mechanism of BTX-A and SNS is complex. The exact mechanisms are still unknown, 
although considerable progress has been made in our understanding. Further research proposals 
are suggested to help further elucidate these mechanisms. 
 
Keywords: botulinum toxin, OnabotulinumtoxinA, sacral neuromodulation, sacral nerve 
stimulation, Botox, Interstim, overactive bladder, detrusor overactivity, mechanism of action, 
urodynamics  
  
Introduction 
Recent long term, high volume, prospective trials have confirmed the efficacy and durability of both 
Botulinum Toxin-A (BTX-A) and sacral neuromodulation (SNM) in treating idiopathic overactive 
bladder (OAB)1,2. Despite the mainstream use of both BTX-A and SNM worldwide in treating OAB, 
the exact mechanisms of action of both treatments are poorly understood. At the ICI-RS meeting 
in Bristol in 2017, a think tank was convened to answer the question “Do we know the exact working 
mechanisms of BTX-A and SNM in the treatment of OAB/detrusor overactivity (DO)?” Although the 
likely answer is ‘no’, the think tank discussed new mechanisms related to both treatments and tried 
to correlate modes of action with some clinical perspectives. Finally, we decided to assess 
urodynamic data before and after these treatments to see if we could glean any further information 
that could help us understand their mode of action. The think tank discussed future research 
strategies to help answer the question and advance knowledge, this will be summarised at the end 
of the manuscript. 
 
Methods 
The literature on BTX-A and SNM was reviewed through PubMed searches, restricted to articles 
published in English. Articles were screened based on titles and abstracts and the most relevant 
articles included. The focus was related to mechanism of action and urodynamic data. 
Pathophysiology of OAB 
To understand the effects of SNM and BTX-A in OAB patients, it is important to summarise briefly 
the proposed pathophysiological mechanisms related to storage symptoms. Several theories, 
alone or in combination, have been proposed to explain the origin of OAB3-9. 
Dysfunction of Afferent Signaling in OAB  
OAB may be a result of increased, abnormal afferent activity, resulting in increased reflex efferent 
signaling. Consequently, voluntary control of micturition is compromised3. 
  
Altered Brain Responses  
OAB patients present abnormal brain responses in areas processing urge and social propriety4,5. 
Alternatively, there might be diminished responses in areas responsible for voluntary voiding. 
According to functional magnetic resonance imaging (f-MRI), poor bladder control is specifically 
associated with inadequate activation of the orbitofrontal cortex.  
Myogenic Theory  
Partial denervation alters smooth muscle properties, which may result in increased excitability, 
coordinated myogenic contractions and augmented bladder pressure6. 
Neurogenic-Myogenic Theory 
 ‘Leakage’ of Acetylcholine (ACh) from parasympathetic nerves during bladder filling may be 
related to micromotion of detrusor bundles and afferent activation7,8. 
Urothelial Theory 
Several compounds (e.g. acetylcholine, ATP, nitric oxide, prostaglandins) are released and/or 
generated by urothelial cells and are be related to cell signaling events9. 
 
BTX-A 
Mechanism of action 
Chemical transmission and botulinum toxins.  Chemical transmission between cells generally 
consists of transmitter release from a prejunctional cell, diffusion in the intercellular space and 
subsequent binding to the cell membrane of a post-junctional cell where it generates a response.  
Classically this process was described at the neuromuscular junction, where acetylcholine (ACh) 
released from motor nerves binds to skeletal muscle nicotinic receptors to initiate muscular 
  
contraction. However, transmission between any combination of nerves, skeletal/cardiac/smooth 
muscle, epithelial and other cell types is possible.  Transmitters are generally, but not exclusively, 
stored in prejunctional intracellular vesicles and released when they dock to the cell membrane 
and exocytose their contents.  Docking is achieved by interaction between SNARE proteins located 
on the cell membrane and vesicles. Botulinum toxins, from Clostridium botulinum bacteria, prevent 
transmitter release by inhibiting vesicular docking.  There are several subtypes (A–G) that cleave 
different docking proteins.  The subtype used most commonly in urological practise, BTX-A, acts 
on a membrane docking protein SNAP-25.  Botulinum toxins are taken into the cell upon binding 
to a receptor site, SV-2, where they are subsequently cleaved into light and heavy chains so that 
the former can exert its effect10. 
OAB and BTX-A.  The original rationale for using BTX-A to reduce OAB was the assumption that 
OAB itself was importantly caused by aberrant release of ACh from parasympathetic efferents to 
cause DO, in much the same way as antimuscarinic agents were assumed to inhibit the activity of 
this ACh in detrusor smooth muscle.  With human detrusor from overactive bladders ACh and ATP 
are functional co-transmitters at the nerve-muscle junction, but this would not affect the basic 
premise as ACh and ATP release were equally attenuated by BTX-A11. 
Since then the cause of OAB/DO has undergone considerable re-evaluation to also include a 
myogenic origin of spontaneous activity; a direct control of detrusor contractile function by the 
overlying mucosa; and augmentation of afferent activity by the mucosa to enhance an afferent-
CNS-efferent loop12,13.  To accommodate these new theories a greater understanding of the action 
of BTX-A is needed. 
BTX-A and bladder function.  A reduction of maximum detrusor pressure, Pdet, would be expected 
through any mode of action for BTX-A and has been reported for adults and children with 
neurogenic or idiopathic DO14-17.  However, an increase of compliance has also been reported that 
implies an additional action in the filling phase15,17.  The time course for changes to Pdet and 
compliance were similar17 but does not imply a common mode of action.  Such changes to Pdet, 
  
and compliance were not discernible in a mouse model with intraluminal application of BTX-A 
(2U/bladder)18.  The latter study did record a significant reduction of afferent nerve firing on filling 
that was independent of detrusor pressure during filling or voiding.  Furthermore, the attenuation 
of firing rate was observed in high and low threshold fibres.  The study suggested either that nerve 
excitability itself was reduced by BTX-A and/or the transduction mechanism that links bladder filling 
to afferent firing had a lower gain. 
There is increasing evidence that also supports an effect of BTX-A on purinergic pathways, 
especially those involved in bladder pathophysiology such as DO19,20. Controversies remain about 
the origin of the decreased detrusor pressure e.g. inhibition of the exocytosis of ACh versus 
decreased expression of muscarinic receptors21,22. In a guinea pig model, cleaved SNAP-25 (an 
indirect marker of a BTX-A effect) products were seen at 24 hours and were expressed in 85% of 
vesicular ACh Transporter positive cholinergic fibres (parasympathetic) and in 42% and 36% of 
tyrosine hydroxylase positive adrenergic (sympathetic) and calcitonin gene related peptide positive 
(sensory) fibres, respectively.  This suggested indirectly that the BTX-A mode of action is apparent 
at both motor and sensory neurones23. 
BTX-A and urothelial function.  The urothelium has been proposed to provide a vital link between 
stressors, such as stretch of the bladder wall during filling or exposure to noxious agents, and 
afferent activation through the release of neuromodulators such as ATP, ACh, nitric oxide (NO) 
and prostaglandins24-26.  Moreover, there is an increase of stressor-induced ATP release in 
pathologies associated with OAB27.  This raises the possibility that BTX-A attenuates stretch-
activated modulator release and therefore diminishes afferent firing.  Such a mechanism could also 
explain the action of BTX-A to increase bladder compliance, especially when pathologically raised.  
ATP release from urothelium is, at least in part via a vesicular route28,29 and the molecular 
apparatus for BTX-A uptake in urothelial cells is present through identification of SV2 and SNAP 
isoforms20.  Moreover, BTX-A reduces stretch-activated ATP release from the bladder in vivo18, 
and from urothelial cells in vitro20,30 to provide the link between its ability to increase bladder 
compliance and reduce afferent firing.  ACh release from urothelium has been studied less, but is 
  
released in greater quantities and more readily than ATP and there is evidence it has a 
paracrine/autocrine action to regulate urothelial ATP release via an M2 receptor31, Figure 1.  
However, release of ACh from urothelial cells in not vesicular25,31, in large part via a CFTR channel 
and BTX-A has no effect on urothelial ACh release in vitro31 or in vivo18.  It is also of interest BTX-
A treatment increases NO release from the bladder wall of normal animals18, or from urothelial cells 
of animals with spinal cord injury30.  As NO is a muscle relaxant its modulation by BTX-A may 
contribute to its effects on voiding detrusor pressure or filling compliance.  The mechanism remains 
to be characterised. 
Overall, changes to in vivo human bladder function after BTX-A administration indicate additional 
effects to its attenuation of transmitter release from efferent nerves.  As more is understood about 
the neuromodulatory actions of the urothelium so too does the emphasis shift for a major action of 
BTX-A on the bladder, away from its modulation of vesicular ACh and ATP release at the nerve-
muscle function to vesicular ATP urothelial release. 
Central effects. In a rat model, BTX-A or normal saline were injected intrathecally into either spinal 
cord transected rats or sham-operated controls32. Spinal cord injury increased basal bladder 
pressure and frequency of contractions when compared to controls and the administration of BTX-
A, unlike normal saline, significantly attenuated contraction frequency and reduced baseline 
pressures towards normal: no animals receiving BTX-A went into urinary retention. Cleaved SNAP-
25 was seen in the superficial dorsal horn of lumbosacral segments in BTX-A treated SCI rats, an 
area where most of the sensory nerves terminate. Cleaved SNAP-25 was not detected in 
preganglionic parasympathetic or motor neurons. Furthermore, BTX-A reduced the intensity of 
CGRP immunoreactivity at L5/6 to values comparable to those observed in spinal intact animals. 
These data were interpreted that BTX-A significant impaired sensory fibres through a mechanism 
involving cleavage of SNAP-25 at terminals in the spinal cord dorsal horn32. Further evidence 
supporting central effects was the observation in rats of retrograde transport of BTX-A after bladder 
injection33 . BTX-A was radiolabelled with technetium-99 and was detected in the dorsal root 
ganglia 6 hrs post-injection and corresponding to about 3% of the injected dose into the bladder.  
  
 
Clinical perspectives on BTX-A that help to understand mechanisms of action 
OnabotulinumtoxinA (Botox, Allergan Ltd, Irvine, CA) received a license to treat both neurogenic 
detrusor overactivity (NDO) at 200 U, secondary to multiple sclerosis and spinal cord injury, and 
idiopathic OAB at 100 U in 2011 and 2013, respectively. In 2000, Schurch first described the use 
of BTX-A to treat NDO in spinal cord injured patients, who suffered from urinary incontinence 
between two intermittent self-catheterisations despite high dosages of anticholinergic drugs34. 
These patients had a significant reduction of urinary incontinence, with decreased reflex volumes 
and increased maximum cystometric capacity (MCC). It was believed that the principal mechanism 
of action in NDO was its effect on efferent parasympathetic pathways. This might be true in part, 
as during the urodynamic voiding phase post BTX-A treatment reduced Pdetmax and post void 
residual (PVR) increased. However, urodynamic data also showed a significant increase of 
maximum cystometric capacity (MCC) and the disappearance of uninhibited bladder contractions, 
and more importantly patients reported a significant benefit from urgency through their bladder 
diaries, none of which could be explained by efferent blockade alone. Subsequently a significant 
reduction in suburothelial P2X3 and TRPV1-positive fibres was demonstrated at 4 weeks after BTX-
A, and more significantly at 16 weeks in bladder biopsies from patients suffering from NDO and 
treated with BTX-A35. P2X3 fibre reduction was significantly correlated to attenuation of urgency 
episodes at 4 and 16 weeks but not to maximum cystometric capacity or detrusor pressures, with 
a similar trend for TRPV1, suggesting a sensory mechanism.  
 
Repeated BTX-A injections are required as effects diminish, but are equally efficacious in OAB and 
NDO with mean duration of effect of 7.6 and 9.0 months, respectively for 100 and 200 U1,36. 
Seroconversion, the presence of toxin neutralising antibodies, was very low but dose-dependent; 
0.4% for 150 U in OAB1 and 1.5% for 200 U in NDO36. In seroconverted patients their request for 
further injections was sooner than those that had not seroconverted (4.9 vs 9.1 months)36.  
 
 
  
Sacral Neuromodulation (SNM) 
SNM is an established alternative for treatment of overactive bladder symptoms in patients who 
failed previous therapies. Although its mechanism of action is not completely understood, several 
studies have demonstrated its efficacy and durability2,37,38. Continuous improvements have been 
introduced and it is now a minimally invasive technique, performed under local anesthesia, and 
might be considered before invasive reconstructive procedures. Briefly, an electrode is implanted 
in the S3 foramen and connected to an implantable pulse generator (IPG). The patient undergoes 
a test phase lasting for days to weeks to determine whether SNM has provided a relevant benefit. 
If results are positive, the IPG is implanted in the upper buttocks 39. At present, InterStim® Therapy 
(Medtronic, Minneapolis, MN, USA) is licensed for treatment of chronic non-obstructive urinary 
retention and symptoms of OAB, including urinary urge incontinence and significant symptoms of 
urgency-frequency alone or in combination, or in patients with idiopathic lower urinary tract 
dysfunction who have failed or could not tolerate more conservative treatments40. 
 
SNM Mechanism of Action 
The goal of SNM is to modulate abnormal sensations and involuntary reflexes of the lower urinary 
tract and restore voluntary control. SNM therapeutic benefits may arise from the effects of electrical 
stimulation on afferent and efferent nerve fibres connecting the pelvic viscera, and spinal 
interneurons to the central nervous system. SNM influences sacral afferents and modulates spinal 
cord reflexes and brain centres involved in lower urinary tract function37. Thus, patients whose 
neural system is not intact may not be ideal candidates for this therapy41.  
 
The stimulator provides an electrical charge to an area near the sacral nerve, resulting in altered 
neural activity. This stimulation depolarises the nerve, generating an action potential which 
propagates along the axon. SNM electrically stimulates somatic afferent nerves in a sacral spinal 
root and sends signals to the CNS that may restore normal bladder function. Activation of somatic 
afferent nerves inhibits bladder sensory pathways and reflex bladder hyperactivity3.  Unlike other 
therapies that target the bladder directly, this approach does not directly influence the bladder or 
  
sphincter muscles42,43. The maximal effect of neuromodulation is not directly attained, indicating 
that neuromodulation induces adaptive changes (i.e. neural plasticity). This could be caused by 
negative modulation of excitatory synapses in the central micturition reflex pathway42.  Evidence 
from cats suggests that reduction of bladder activity occurs primarily in the CNS by inhibition of the 
ascending or descending pathways of the spinobulbospinal micturition reflex44.  However, 
experiments show that SNM delivers graded responses dependent on stimulus protocols45-47. The 
inhibitory effects on bladder contraction may be mediated by both afferent and efferent 
mechanisms. Lower intensities of stimulation may activate large, fast-conducting fibres acting 
through the afferent limb of the micturition reflex arc in SNM. Higher intensities may additionally act 
through the efferent limb45.  
 
The effects of acute electrical stimulation frequency and amplitude on the dorsal nerve of the penis 
(DNP), pudendal nerve (PN) and S1 sacral nerve on isovolumetric reflex bladder contractions and 
maximum cystometric capacity was studied in anaesthetised cats46. There was no significant 
difference in the maximum extent to which the optimised frequency or amplitude inhibited bladder 
contractions or increased cystometric capacity. However, the range of amplitudes and frequencies 
for maximum inhibition was larger for DNP stimulation than for PN or S1 stimulation46. 
 
Three rate-setting sequences have been tested in OAB female patients undergoing SNM: 5.2, 14 
and 25 Hz47.  There were significant effects on the number of incontinence episodes and pad 
changes per day.  At 5.2 Hz there were more incontinence episodes and pad changes than at 14 
or 25 Hz.  The number of adverse events was similar across the three rate settings, but 
programming-related adverse events were lowest in the 14 Hz group47. 
 
  
Can we gain valuable information on the mechanism of action of BTX-A and SNS from 
urodynamic or other tests? 
Patient selection is a key factor in achieving optimal clinical outcomes with BTX-A and SNM. 
Clinical factors, such as severity of urge incontinence episodes, age, and comorbidity may help to 
guide treatment choice48,49. However, improving our understanding their mechanism of action may 
provide a more satisfactory way to guide patient selection, and urodynamic studies may prove 
valuable in this regard in identifying predictive factors for success and complications.   
 
BTX-A. Results on the effect of intravesical injections of BTX-A on urodynamic variables supports 
the hypothesis that it has both afferent and efferent mechanisms of action in OAB. A randomised 
placebo-controlled study in idiopathic OAB showed a dose-dependent improvement of mean 
cystometric capacity, with 100 U leading to a mean improvement by 71 ml at 12-week follow-up50. 
Improvements in the mean volume at first involuntary detrusor contraction by 83 ml with 100 U also 
confirm its effect on the afferent micturition pathway. A systematic review of studies also showd 
consistent improvements in filling-phase parameters of mean maximum cystometric capacity and 
maximum detrusor pressure following BTX-A injection of 32% and -31%, respectively51. The 
presence or absence of DO has been shown in several studies not to influence the outcome as 
assessed by patient-reported outcome measures.  However, this may be due to limitations in 
assessment, as these studies were based on standard cystometry which itself has a poor negative 
predictive value in diagnosing DO52. To more accurately determine whether the presence and 
severity of DO is a predictor of poor outcome, future studies should be undertaken using ambulatory 
urodynamics.  
 
Urodynamic findings pre-and post-injection in five patients who did not respond to BTX-A injections 
for idiopathic DO habe been reviewed53.  Baseline maximum detrusor pressure during filling of 
greater than 110 cmH2O had a sensitivity and specificity of 86% and 100%, respectively, in 
predicting a poor response to treatment. However, future study in a larger cohort of patients is 
warranted to validate these findings. The effect of BTX-A on voiding urodynamic parameters have 
  
not been well-studied in large randomised-controlled trials. However the urodynamic voiding 
parameters in 67 patients treated with 200U of BTX-A have been reviewed and it was found that 
patients requiring clean intermittent self-catheterisation (CISC) had a lower baseline Qmax and 
detrusor contractility54. A projected isovolumetric pressure (PIP1) of ≤50 cmH2O in 
women (sensitivity 83%; specificity 70%) and bladder contractility index (BCI) ≤120 in men 
(sensitivity 70%; specificity 79%) predicted the need for CISC. More recently, the outcomes of 290 
patients treated with BTX-A for OAB have been reviewed, where it was found that a voiding 
efficiency of <89% ((voided volume/total bladder capacity) X100) was a predictor of a high post-
void residual (>200 ml)55. However, these studies were limited by their sample size and 
retrospective nature. Larger prospective studies of filling and voiding parameters are required to 
identify predictive factors for poor outcomes and the need for CISC, to aid patient counselling and 
selection.  
 
An alternative drug delivery technique using BTX-A encapsulated in liposomes has been trialled in 
a double-blind randomised-controlled trial, with significant improvements in frequency and urgency 
and no increased risk of urinary retention compared to placebo56. Urodynamic variables were not 
assessed in this study but in a preliminary animal study a significant reduction in inter-contraction 
interval was measured, with no effect on voiding detrusor contraction strength suggesting an 
afferent effect without significant efferent response57. Further studies of alternative drug delivery 
techniques (liposomes/electromotive drug administration) should include a urodynamic 
assessment of storage and voiding function. 
 
SNS. A study analysing pre and post-operative urodynamic findings in 33 women with IDO reported 
improvements in filling-phase parameters of median maximum detrusor pressure (29% reduction), 
median amplitude of the highest involuntary detrusor contraction (24% reduction), and maximum 
cystometric capacity (33% improvement) at 6 months after implantation58. However, effects on the 
voiding parameters of urethral resistance and bladder contraction strength were not significantly 
different compared to baseline. This may suggest that SNM does not have a direct role in the 
  
efferent arm of the micturition reflex, and rather affects voiding function through a different, possibly 
central, mechanism. This has also been suggested by neurophysiological studies using EEG 
recordings during SNM by S3 stimulation, which showed increased activity in the sensory cortex59. 
Another study of 19 women who underwent SNM for OAB highlighted a potential role for urethral 
function in its mode of action60. Urethral instability (defined as urethral pressure variations of more 
than 15 cmH20) disappeared in 54% of successfully treated patients, a change that was not seen 
for DO. Furthermore, 84% of patients had urethral pressure fluctuations of >30 cmH20 prior to 
treatment, but this was seen in only 29% following implantation. Again, significant improvements 
were seen in mean volume at first sensation (from 98 ms to 235 ml) and mean peak detrusor 
pressure during filling (from 42 cmH20 to 25 cmH20), and has been confirmed by others61. Another 
study of 54 patients confirmed the effects of SNM on filling-phase parameters, with improvements 
in mean bladder volume at first sensation by 57% and maximum cystometric capacity by 29%. As 
is the case with studies on BTX-A, the presence of DO has no influence on the clinical success of 
SNM62. These findings have been confirmed in other studies with similar magnitudes of effect63. 
When ambulatory urodynamics were assessed before and after SNM, there was no significant 
difference in the maximum amplitude of detrusor contraction or number of detrusor contractions, 
but the detrusor activity index (DAI) correlated significantly with clinical success64.  
 
The use of neurophysiological testing of somatosensory evoked potentials (SEP’s) of the pudendal 
and posterior tibial nerves has shown that the mechanism of action of SNM is via afferent pathways 
at the cortical level, and preliminary evidence suggests that the pattern of SEP and its modification 
by SNM could be used as a predictive factor of successful clinical outcome65. This promising finding 
needs to be reproduced to determine its clinical utility.    
 
Conclusions 
The exact working mechanisms of BTX-A and SNM are complicated and are currently not fully 
known, but a considerable amount of research has yielded information about potential 
mechanisms. BTX-A appears to have both motor and sensory effects as seen in clinical practice 
  
and further evidenced by urodynamic data, human biopsy work and animal models. SNM is likely 
to modulate abnormal sensory signaling and to correct any imbalance seen between sensory and 
motor signaling related to the bladder. Further research into the working mechanisms of these 
treatments will help us further understand the working mechanisms of BTX-A and SNM but also 
provide further insights into the pathophysiology of OAB.  
 
 
 
 
  
  
Research Proposals 
BTX 
• Further research to expand on central effects and confirmation of retrograde transport to 
DRGs and CNS in OAB / DO 
• Further explore the role of the urothelium and the exact mechanisms involved of BTX-A at 
this level 
• Effect on signaling in suburothelium and interstitial cells and mechanism of action on 
sensory nerves 
• More human bladder tissue orientated research 
• Explore the effect of BTX-A at time of clinical relapse 
• Explore the possibility of modifying BTX-A such that its effects are on sensory nerves in 
isolation 
• Liposome / Lipotoxin / other strategies to breach the urothelium and allow BTX-A delivery 
into the bladder wall 
• Bladder based injections only – large scale study to ascertain if the beneficial effects of the 
toxin can be maintained whilst keeping voiding dysfunction to a minimal 
• Analysis of poor responders to BTX-A to ascertain reason why 
• Ambulatory urodynamic studies pre and post injection may help to identify stronger 
predictive factors for success of BTX-A  
• Larger prospective studies of urodynamic and contractility parameters are required to 
identify predictive factors for poor outcomes and need for CISC 
 
SNS 
• Comparison of tibial nerve vs pudendal vs SNM mechanisms of action 
• Parallels drawn from mechanisms of SNM for bowel dysfunction 
• Central effects of SNM as characterised by next generation fMRI studies 
• Which patient factors determine success in SNM? 
  
• Can combination of SNM and pharmacotherapy (e.g. antimuscarinics, mirabegron, opioids) 
increase efficacy? 
• What is the onset/offset of action in SNM? 
• Alteration of stimulation parameters – frequency, cycling and impact on efficacy  
• Further research into SNM for NDO and in particular in acute SCI 
• Larger prospective studies comparing outcomes of SNM vs BTX-A in terms of urodynamic 
parameters 
• Whether ambulatory urodynamic parameters, such as the DAI, can predict success in SNM 
• Further evaluation of neurophysiological tests, such as somatosensory evoked potentials, 
are needed to answer the following questions: do they correlate with clinical outcome? Can 
they be used as predictive factors? Can they help determine optimal stimulation parameters 
for SNM 
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Figure 1.  Proposed pathways for stretch-evoked urothelial ATP and acetylcholine (ACh) release 
according to current experimental data.  ACh is importantly (but not exclusively) released via CFTR 
channels under much lower stresses compared to ATP release.  ATP release is increased by 
muscarinic (M2) receptor activation via routes that include vesicular exocytosis and through 
connexion hemichannels.  ATP may than exert autocrine effects, either directly or via its breakdown 
products from ectoATPase activity, through purinergic (P2Y or P2X receptors) or adenosine (A1) 
receptors to modulate further ATP release.  ATP may also signal to sensory nerves or interstitial 
cells in the suburothelium, or even directly to detrusor myocytes.  The diagram does not show the 
role of other modulators of ATP release, such as low pH or variations of trans-urothelial membrane 
potential – see ref 27 for further details.  
 
